Skip to main content
. Author manuscript; available in PMC: 2020 Mar 28.
Published in final edited form as: Nanoscale. 2019 Mar 28;11(13):6192–6205. doi: 10.1039/c8nr08970a

Figure 8:

Figure 8:

Cell viability of brain tumor cell lines; (A) SJGBM2, (B) CHLA200, (C) U87 and (D) CHLA266 exposed to free temozolomide, free epirubicin or the mixture of temozolomide and epirubicin treatment. Data is presented as percent of non-treated control cells +/− SEM. #p<0.05 compared to control, *p<0.05 combined drug treatment compared to free epirubicin.